2seventy bio Inc (TSVT) kicked off at the price of $2.64: Venture capitalists have an exciting new opportunity

2seventy bio Inc (NASDAQ: TSVT) on Monday, plunged -9.28% from the previous trading day, before settling in for the closing price of $2.91. Within the past 52 weeks, TSVT’s price has moved between $2.78 and $6.40.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 91.91%. The company achieved an average annual earnings per share of 81.88%. With a float of $48.33 million, this company’s outstanding shares have now reached $51.51 million.

Considering the fact that the conglomerate employs 274 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 51.77%, operating margin of -313.09%, and the pretax margin is -207.25%.

2seventy bio Inc (TSVT) Breakdown of a Key Holders of the stock

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of 2seventy bio Inc is 6.31%, while institutional ownership is 87.85%. The most recent insider transaction that took place on Dec 13 ’24, was worth 7,393. In this transaction an insider of this company sold 2,287 shares at a rate of $3.23, taking the stock ownership to the 153,479 shares. Before that another transaction happened on Dec 13 ’24, when Company’s Officer proposed sale 10,341 for $3.34, making the entire transaction worth $34,539.

2seventy bio Inc (TSVT) Recent Fiscal highlights

Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 81.88% per share during the next fiscal year.

2seventy bio Inc (NASDAQ: TSVT) Trading Performance Indicators

2seventy bio Inc (TSVT) is currently performing well based on its current performance indicators. A quick ratio of 4.95 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.93.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.86, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.47 in one year’s time.

Technical Analysis of 2seventy bio Inc (TSVT)

Compared to the last year’s volume of 0.48 million, its volume of 0.8 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 21.85%. Additionally, its Average True Range was 0.24.

During the past 100 days, 2seventy bio Inc’s (TSVT) raw stochastic average was set at 0.93%, which indicates a significant decrease from 3.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.39% in the past 14 days, which was lower than the 70.02% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $3.75, while its 200-day Moving Average is $4.37. Nevertheless, the first resistance level for the watch stands at $2.86 in the near term. At $3.07, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.19. If the price goes on to break the first support level at $2.52, it is likely to go to the next support level at $2.40. Now, if the price goes above the second support level, the third support stands at $2.18.

2seventy bio Inc (NASDAQ: TSVT) Key Stats

Market capitalization of the company is 133.89 million based on 51,588K outstanding shares. Right now, sales total 100,390 K and income totals -217,570 K. The company made 13,530 K in profit during its latest quarter, and -9,930 K in sales during its previous quarter.